Loading ETF profile…
The Amplify Weight Loss Drug & Treatment ETF (THNR) offers investors a way to access international firms poised to benefit financially from advancements in weight management pharmaceuticals. Its primary objective is to mirror the investment performance (before any fees or expenses) of the VettaFi Weight Loss Drug & Treatment Index.
| Symbol | Name | Weight | Market Value |
|---|---|---|---|
| NVO | Novo Nordisk A/S | 9.78% | $429.31K |
| LLY | Eli Lilly & Co | 9.44% | $414.49K |
| SRRK | Scholar Rock Holding Corp | 5.67% | $249.02K |
| VKTX | Viking Therapeutics Inc | 5.53% | $242.85K |
| HIMS | Hims & Hers Health Inc | 5.33% | $234.16K |
| ABBV | AbbVie Inc | 5.22% | $229.13K |
| 1801.HK | Innovent Biologics Inc | 5.00% | $219.44K |
| ARWR | Arrowhead Pharmaceuticals Inc | 4.99% | $219.12K |
| 4519.T | Chugai Pharmaceutical Co Ltd | 4.58% | $201.12K |
| 1093.HK | CSPC Pharmaceutical Group Ltd | 4.57% | $200.56K |
| MRK | Merck & Co Inc | 4.57% | $200.54K |
| AZN | AstraZeneca PLC | 4.56% | $200.31K |
| ROP.SW | Roche Holding AG | 4.56% | $200.29K |
| AMGN | Amgen Inc | 4.53% | $199.02K |
| REGN | Regeneron Pharmaceuticals Inc | 4.52% | $198.39K |
| PFE | Pfizer Inc | 4.42% | $193.91K |
| ZEAL.CO | Zealand Pharma A/S | 3.36% | $147.68K |
| KLRA | Kailera Therapeutics Inc | 2.40% | $105.40K |
| 1276.HK | Jiangsu Hengrui Pharmaceuticals Co Ltd | 2.26% | $99.35K |
| 128940.KS | Hanmi Pharm Co Ltd | 2.15% | $94.47K |
| — | Cash & Other | 2.04% | $89.44K |
| AGPXX | Invesco Government & Agency Portfolio 12/31/2031 | 0.53% | $23.07K |